← ANALYST RATINGS · TIPRANKS
Danaher (DHR): analyst forecast and price target
Analyst consensus
Strong Buy12 Buy1 Hold0 Sell
Ratings of 13 analysts in the last 3 months · top analysts only12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $238, the highest $255, the lowest $200. The average is +4.1% from the last price of $229.
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $220 → $250+13.6% | Buy | +9.2% | Reiterated | 16.10.26on TipRanks Oct 17 08:14 | 0.0% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $242 → $247+2.1% | Buy | +7.8% | Reiterated | 13.10.26on TipRanks 20:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $242 → $249+2.9% | Buy | +8.7% | Reiterated | 13.10.26on TipRanks 20:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $241 → $246+2.1% | Buy | +7.4% | Reiterated | 13.10.26on TipRanks 20:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $229 → $237+3.5% | Hold | +3.5% | Reiterated | 13.10.26on TipRanks 20:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $240 → $247+2.9% | Buy | +7.8% | Reiterated | 13.10.26on TipRanks 20:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $225 → $249+10.7% | Buy | +8.7% | Reiterated | 13.10.26on TipRanks 20:05 | — | |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $236 → $255+8.1% | Buy | +11.3% | Reiterated | 13.10.26on TipRanks 08:41 | +0.8%next day +1.9% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $220 → $240+9.1% | Buy | +4.8% | Assigned | 12.10.26on TipRanks 09:00 | +0.7%next day +0.8% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $230 → $255+10.9% | Buy | +11.3% | Reiterated | 09.10.26on TipRanks 08:01 | +0.5%next day +0.7% · 5 days +6.2% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $230 → $255+10.9% | Buy | +11.3% | Reiterated | 07.10.26on TipRanks 03:55 | +1.6%next day 0.0% · 5 days +3.8% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $210 → $250+19.0% | Buy | +9.2% | Reiterated | 05.10.26on TipRanks 07:40 | +2.7%next day −3.1% · 5 days −0.4% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $215 → $250+16.3% | Buy | +9.2% | Reiterated | 04.10.26on TipRanks Oct 5 07:16 | +2.7%next day −3.1% · 5 days −0.4% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $200 → $250+25.0% | Buy | +9.2% | Reiterated | 01.10.26on TipRanks 08:35 | −4.6%next day +0.3% · 5 days +1.4% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $230 | Buy | +0.4% | Reiterated | 21.09.26on TipRanks 06:15 | +0.4%next day +2.4% · 5 days +6.3% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $210 | Buy | −8.3% | Reiterated | 18.09.26on TipRanks 10:25 | −0.5%next day +0.4% · 5 days +4.7% | ↗ |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $250 | Buy | +9.2% | Initiated | 13.09.26on TipRanks 21:15 | +2.0%next day +3.5% · 5 days +4.3% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $200 | Hold | −12.7% | Reiterated | 27.07.26on TipRanks 08:39 | +2.6%next day +1.1% · 5 days −2.0% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $230 | Buy | +0.4% | Assigned | 23.07.26on TipRanks Jul 24 09:40 | +8.7%next day −0.6% · 5 days +1.4% | ↗ |
| Aristotelis Moutopoulos★★★★★★★★★★#9693 · hits 56% · avg −1.5% | DZ BANK AG | $210 | Buy | −8.3% | Reiterated | 22.07.26on TipRanks Sep 10 03:15 | +0.2%next day +8.7% · 5 days +12.1% | |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $250 → $240−4.0% | Buy | +4.8% | Assigned | 22.07.26on TipRanks Jul 24 05:14 | +0.2%next day +8.7% · 5 days +12.1% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 22.07.26on TipRanks Jul 24 05:14 | +0.2%next day +8.7% · 5 days +12.1% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $260 → $220−15.4% | Buy | −3.9% | Reiterated | 22.07.26on TipRanks Jul 24 05:14 | +0.2%next day +8.7% · 5 days +12.1% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $232 → $230−0.9% | Buy | +0.4% | Reiterated | 06.07.26on TipRanks 08:50 | −3.0%next day +0.8% · 5 days +3.7% | ↗ |
| Sidharth Sahoo★★★★★★★★★★#9090 · hits 43% · avg −0.9% | HSBC | $270 → $230−14.8% | Buy | +0.4% | Reiterated | 03.06.26on TipRanks 05:35 | +1.8%next day +4.4% · 5 days +6.9% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | — | Hold | — | Downgrade | 01.06.26on TipRanks 16:15 | −2.2%next day +1.8% · 5 days +9.9% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $249 → $245−1.6% | Buy | +7.0% | Reiterated | 22.04.26on TipRanks 22:00 | −2.6%next day −1.5% · 5 days −1.2% | ↗ |
| Ed Ridley-Day★★★★★★★★★★#5780 · hits 54% · avg +8.0% | Rothschild & Co Redburn | $220 → $205−6.8% | Hold | −10.5% | Reiterated | 17.04.26on TipRanks 04:55 | −0.7%next day +0.6% · 5 days −9.5% | ↗ |
| Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% | KeyBanc | $310 | Buy | +35.3% | Assigned | 18.12.25on TipRanks 04:15 | 0.0%next day −0.7% · 5 days +0.5% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $235 | Buy | +2.6% | Reiterated | 22.10.25on TipRanks Oct 23 02:45 | −0.7%next day +1.5% · 5 days −4.8% | ↗ |
| Unknown Analyst | Raymond James | — | Hold | — | Reiterated | 22.10.25on TipRanks 07:50 | −0.7%next day +1.5% · 5 days −4.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Danaher
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $228 at a price of $222 (+2.8%); now: $237 at $229 (+3.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 1 | 0 | 0 |
| Buy | 21 | 22 | 22 | 23 | 25 | 15 |
| Hold | 1 | 4 | 5 | 5 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 21.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.92 (from $1.90 to $1.99). Last quarter: $1.94.
Sales
Next quarter’s sales estimate — $6.6B (from $6.5B to $6.7B). Last quarter: $6.3B.
Best top-analyst consensus in the sector · Healthcare
About Danaher
- CEO: Julie Sawyer Montgomery
- Employees: 59,000
- 2200 Pennsylvania Avenue, NW, Washington, DC, 20037-1701, US
- www.danaher.com
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, w
Data from the stock’s TipRanks forecast page, read 22 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗